Alan S. Brown, M.D.
Director, Division of Cardiology and the Lipid Clinic Advocate Lutheran General Hospital
Clinical Associate Professor, Loyola University Medical Center
Estimated Time of Talk
45 min webcast = 0.75 credits
15 min Q&A = 0.25 credits
Total = 1.00 credits
This webinar will cover clinical implications and therapeutic approaches to patients with hypertriglyceridemia.
- Understand the effect of hypertriglyceridemia on CHD risk.
- Review treatment strategies to reduce risk of pancreatitis and CHD events.
- Review appropriate therapies for patients with elevated triglycerides.
Conflicts of Interest
Speaker- Amgen, Regeneron, Sanofi, Advisory Board- Amarin, Kastle, Kowa, Pfizer, Sanofi
This enduring material activity, Reducing Cardiovascular Risk in the Patient with Elevated Triglycerides, has been reviewed and is acceptable for up to 1.00 prescribed credits by the American Academy of Family Physicians. Term of approval begins May 1, 2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.